Literature DB >> 29198458

Clinical Outcomes According to Fractional Flow Reserve or Instantaneous Wave-Free Ratio in Deferred Lesions.

Joo Myung Lee1, Eun-Seok Shin2, Chang-Wook Nam3, Joon-Hyung Doh4, Doyeon Hwang5, Jonghanne Park5, Kyung-Jin Kim5, Jinlong Zhang5, Chul Ahn6, Bon-Kwon Koo7.   

Abstract

OBJECTIVES: The authors investigated 2-year clinical outcomes according to fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) values in deferred lesions.
BACKGROUND: Invasive physiological indices such as FFR or iFR are used in clinical practice to select ischemia-causing stenosis and to guide the treatment strategy for patients with coronary artery disease.
METHODS: From the 3V FFR-FRIENDS (3-Vessel Fractional Flow Reserve for the Assessment of Total Stenosis Burden and Its Clinical Impact in Patients With Coronary Artery Disease) study, 821 deferred lesions (n = 374) with both FFR and iFR available were included in this study. The primary outcome was major adverse cardiac events (MACE) (a composite of cardiac death, myocardial infarction, and ischemia-driven revascularization) at 2 years. The lesions were classified according to FFR and iFR cutpoints into concordant normal (Group 1: FFR >0.80 and iFR >0.89), high FFR and low iFR (Group 2: FFR >0.80 and iFR ≤0.89), low FFR and high iFR (Group 3: FFR ≤0.80 and iFR >0.89), and concordant abnormal (Group 4: FFR ≤0.80 and iFR ≤0.89).
RESULTS: Deferred lesions with low FFR (≤0.80) or low iFR (≤0.89) showed significantly higher rates of 2-year MACE, compared with high FFR (>0.80) or high iFR (>0.89), respectively (7.2% in low FFR vs. 2.4% in high FFR; p < 0.001; 8.1% in low iFR vs. 2.4% in high iFR; p < 0.001). Both FFR and iFR showed significant association with occurrence of MACE as continuous values (hazard ratio [HR] of FFR: 0.570, 95% confidence interval [CI]: 0.337 to 0.963; p < 0.001; HR of iFR: 0.350, 95% CI: 0.217 to 0.567; p < 0.001). When comparing the discriminant ability between FFR and iFR, the c-index was comparable between FFR and iFR (c-index 0.677 vs. 0.685; p = 0.857). Among 4 groups classified according to FFR and iFR levels, only Group 4 with concordant abnormal results showed significantly higher risk of MACE, compared with group 1 (HR: 7.708, 95% CI: 2.621 to 22.667; p < 0.001).
CONCLUSIONS: Both FFR and iFR showed significant association with future risk of MACE in deferred lesions. The discordant results between FFR and iFR were not associated with the increased risk of MACE. The risk of MACE was significantly increased only in lesions with abnormal results of both FFR and iFR.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary artery disease; discordance; fractional flow reserve; instantaneous wave free ratio; ischemia; prognosis

Mesh:

Year:  2017        PMID: 29198458     DOI: 10.1016/j.jcin.2017.07.019

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  12 in total

Review 1.  Consensus document for invasive coronary physiologic assessment in Asia-Pacific countries.

Authors:  Hak Seung Lee; Joo Myung Lee; Chang-Wook Nam; Eun-Seok Shin; Joon-Hyung Doh; Neng Dai; Martin K C Ng; Andy S C Yong; Damras Tresukosol; Ajit S Mullasari; Rony Mathew; Praveen Chandra; Kuang-Te Wang; Yundai Chen; Jiyan Chen; Kai-Hang Yiu; Nils P Johnson; Bon-Kwon Koo
Journal:  Cardiol J       Date:  2019-06-21       Impact factor: 2.737

2.  Association of quantitative flow ratio-derived microcirculatory indices with anatomical-functional discordance in intermediate coronary lesions.

Authors:  Liang Geng; Yuan Yuan; Peizhao Du; Liming Gao; Yunkai Wang; Jiming Li; Wei Guo; Ying Huang; Qi Zhang
Journal:  Int J Cardiovasc Imaging       Date:  2021-05-31       Impact factor: 2.357

3.  High contrast power Doppler imaging in side-viewing intravascular ultrasound imaging via angular compounding.

Authors:  Graham C Collins; Bowen Jing; Brooks D Lindsey
Journal:  Ultrasonics       Date:  2020-06-02       Impact factor: 2.890

4.  3-D Intravascular Characterization of Blood Flow Velocity Fields with a Forward-Viewing 2-D Array.

Authors:  Brooks D Lindsey; Bowen Jing; Saeyoung Kim; Graham C Collins; Muralidhar Padala
Journal:  Ultrasound Med Biol       Date:  2020-06-30       Impact factor: 2.998

Review 5.  Clinical use of physiological lesion assessment using pressure guidewires: an expert consensus document of the Japanese association of cardiovascular intervention and therapeutics-update 2022.

Authors:  Yoshiaki Kawase; Hitoshi Matsuo; Shoichi Kuramitsu; Yasutsugu Shiono; Takashi Akasaka; Nobuhiro Tanaka; Tetsuya Amano; Ken Kozuma; Masato Nakamura; Hiroyoshi Yokoi; Yoshio Kobayashi; Yuji Ikari
Journal:  Cardiovasc Interv Ther       Date:  2022-05-11

6.  Understanding Fractional Flow Reserve/Instantaneous Wave-Free Ratio Discordance Can Provide Coronary Clarity.

Authors:  David M Tehrani; Arnold H Seto
Journal:  J Am Heart Assoc       Date:  2022-05-02       Impact factor: 6.106

Review 7.  Physiologic Lesion Assessment to Optimize Multivessel Disease.

Authors:  Murtaza Bharmal; Morton J Kern; Gautam Kumar; Arnold H Seto
Journal:  Curr Cardiol Rep       Date:  2022-03-02       Impact factor: 3.955

8.  Computational instantaneous wave-free ratio (IFR) for patient-specific coronary artery stenoses using 1D network models.

Authors:  Jason M Carson; Carl Roobottom; Robin Alcock; Perumal Nithiarasu
Journal:  Int J Numer Method Biomed Eng       Date:  2019-11       Impact factor: 2.648

Review 9.  Functional Approach for Coronary Artery Disease: Filling the Gap Between Evidence and Practice.

Authors:  Joo Myung Lee; Joon Hyung Doh; Chang Wook Nam; Eun Seok Shin; Bon Kwon Koo
Journal:  Korean Circ J       Date:  2018-03       Impact factor: 3.243

Review 10.  Non-hyperaemic pressure ratios to guide percutaneous coronary intervention.

Authors:  Michael Michail; Udit Thakur; Ojas Mehta; John M Ramzy; Andrea Comella; Abdul Rahman Ihdayhid; James D Cameron; Stephen J Nicholls; Stephen P Hoole; Adam J Brown
Journal:  Open Heart       Date:  2020-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.